Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Claritin Patent Ruling Unlikely To Affect Clarinex Exclusivity

Executive Summary

The outcome of Schering-Plough's Claritin patent litigation is unlikely to have a significant effect on the exclusivity for the successor drug Clarinex
Advertisement

Related Content

Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Claritin Patent Case May Define Value Of Metabolite Patents
Claritin Patent Case May Define Value Of Metabolite Patents
Schering Consumer Strategy: Switch Claritin OTC, Establish Clarinex By DTC
Schering Consumer Strategy: Switch Claritin OTC, Establish Clarinex By DTC
Advertisement
UsernamePublicRestriction

Register

PS040317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel